Evaxion Biotech AS (EVAX)
3.98
+0.07
(+1.79%)
USD |
NASDAQ |
May 02, 16:00
4.02
+0.04
(+1.01%)
After-Hours: 20:00
Evaxion Biotech Total Liabilities (Quarterly): 17.63M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.63M |
| September 30, 2023 | 14.68M |
| June 30, 2023 | 14.22M |
| March 31, 2023 | 13.91M |
| December 31, 2022 | 13.72M |
| September 30, 2022 | 13.90M |
| June 30, 2022 | 13.85M |
| March 31, 2022 | 14.69M |
| Date | Value |
|---|---|
| December 31, 2021 | 7.726M |
| September 30, 2021 | 7.466M |
| June 30, 2021 | 5.828M |
| March 31, 2021 | 7.121M |
| December 31, 2020 | 4.927M |
| September 30, 2020 | 3.372M |
| December 31, 2019 | 1.722M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
1.722M
Minimum
Dec 2019
17.63M
Maximum
Dec 2023
10.32M
Average
13.72M
Median
Dec 2022
Total Liabilities (Quarterly) Benchmarks
| Ascendis Pharma A/S | 1.074B |
| DBV Technologies SA | 42.80M |
| Cellectis SA | 249.58M |
| Adaptimmune Therapeutics PLC | 243.10M |
| Akari Therapeutics PLC | 4.584M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 12.89M |
| Shareholders Equity (Quarterly) | -4.739M |
| Debt to Equity Ratio | -1.825 |
| Current Ratio | 1.179 |